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Objectives
To assess telephone monitoring as a method of central
monitoring for clinical trials.
Methods
Determining how academic clinical trials units can opti-
mise data quality via central monitoring methods is an
important factor in trial management. In the AZURE
trial, it became apparent from site monitoring that the
endpoint dates as defined in EORTC literature [1] were
misinterpreted at site. Although a training programme
was initiated, some sites were seen to report date of
confirmation rather than date of onset/suspicion as
required. Therefore the focus of site monitoring was
changed to review this critical endpoint data. Due to
limited trial monitoring resources, a review of telephone
monitoring was implemented.
A pilot phase was implemented to review the practi-
calities and possible results which could be obtained
using telephone monitoring. During the pilot phase 17
trial endpoints were reviewed which had been verified
by both site and telephone monitoring.
Results
Agreement between site and telephone monitoring was
achieved on 12/17 events during the pilot phase. Tele-
phone monitoring was implemented and a total of 105
events were reviewed, some cases with multiple queries.
Agreement between telephone monitoring and the Case
Report Forms was found on 81/105 events. Discrepan-
cies between the Case Report Form and telephone mon-
itoring lead to a median amendment of the endpoint
date of 9.0 days (IQR 7.0 - 23.0 days). In addition, 23
priority data queries were also identified for telephone
monitoring which required clarification of diagnoses and
addition of missing dates of suspicion with censoring of
patients’ data if unresolved.
Conclusions
Our findings indicate that although site monitoring
remained the gold standard method of source data veri-
fication, telephone monitoring is a useful method for
validating endpoint data when site monitoring resources
are not available. The success of telephone monitoring
was strongly related to the experience of the person at
site involved with the review. When talking to less
experienced staff, it was difficult to remotely navigate
through the notes and pick up earlier scans/ recur-
rences. Also, if a participant had more than one recur-
rence it was found to be difficult to piece together all
the available information over the phone.
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